Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) has received a consensus rating of “Moderate Buy” from the five research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $4.67.
A number of equities analysts have recently commented on STIM shares. Citigroup restated a “market outperform” rating on shares of Neuronetics in a research note on Tuesday, July 21st. Wall Street Zen upgraded Neuronetics from a “sell” rating to a “hold” rating in a report on Sunday, July 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research report on Monday, September 14th. BTIG Research reaffirmed a “buy” rating and issued a $6.00 target price on shares of Neuronetics in a research report on Thursday, September 17th. Finally, B. Riley Financial assumed coverage on Neuronetics in a report on Friday, September 11th. They set a “buy” rating on the stock.
Get Our Latest Stock Report on STIM
Insider Activity
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Madryn Asset Management LP acquired a new stake in Neuronetics in the second quarter valued at approximately $24,102,634. BlackRock Inc. acquired a new position in shares of Neuronetics during the second quarter worth $776,000. FourWorld Capital Management LLC increased its holdings in shares of Neuronetics by 59.9% during the first quarter. FourWorld Capital Management LLC now owns 1,489,322 shares of the company’s stock worth $2,160,000 after buying an additional 558,072 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Neuronetics during the second quarter worth $130,000. Finally, Fielder Capital Group LLC bought a new position in shares of Neuronetics in the 2nd quarter valued at $30,000. 53.59% of the stock is owned by institutional investors.
Neuronetics Stock Down 0.5%
Shares of STIM opened at $2.13 on Tuesday. The business’s 50 day simple moving average is $2.73 and its 200-day simple moving average is $1.93. Neuronetics has a one year low of $0.80 and a one year high of $3.44. The company has a market capitalization of $162.31 million, a P/E ratio of -4.84 and a beta of 1.19. The company has a debt-to-equity ratio of 2.84, a current ratio of 1.88 and a quick ratio of 1.69.
Neuronetics (NASDAQ:STIM – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.07. Neuronetics had a negative return on equity of 125.11% and a negative net margin of 19.62%. The company had revenue of $41.57 million during the quarter, compared to analysts’ expectations of $40.17 million. As a group, sell-side analysts predict that Neuronetics will post -0.33 EPS for the current fiscal year.
Neuronetics Company Profile
Neuronetics, Inc is a medical technology company focused on developing and commercializing noninvasive treatments for mental health conditions. The company’s primary product is the NeuroStar Advanced Therapy system, which uses transcranial magnetic stimulation (TMS) to deliver targeted magnetic pulses to areas of the brain associated with mood and related symptoms.
NeuroStar TMS Therapy is cleared by the U.S. Food and Drug Administration for the treatment of major depressive disorder in adults and adolescents, obsessive-compulsive disorder in adults, and certain associated indications.
Featured Articles
- Five stocks we like better than Neuronetics
- 3 Unique ETFs With Strong Momentum for the End of the Year
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
- Schneider Just Paid Up for PTC—Is the SaaSpocalypse Overdone?
- Delta Air Lines Faces a Fuel Crisis—But There’s a Silver Lining
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.
